10-Q: Regen Biopharma Reports Increased Net Loss in Q1 2025 Due to Derivative Losses

Regen Biopharma's Q1 2025 results show an increased net loss primarily due to derivative losses, despite a reduction in operating expenses.

Summary

• Regen Biopharma, Inc. reported financial results for the quarter ended December 31, 2024.
• Net revenue remained consistent at $59,065 compared to the same period in 2023.
• Operating expenses decreased from $181,847 in Q1 2023 to $120,443 in Q1 2025, mainly due to lower consulting and professional fees, and research and development expenses.
• The company experienced a net loss of $515,384 for the quarter ended December 31, 2024, compared to a net loss of $144,933 for the same period in 2023.
• The increased net loss is primarily attributed to a derivative loss of $416,016.
• The working capital deficit increased by $461,670 from September 30, 2024, to December 31, 2024, primarily due to an increase in derivative liability.
• As of December 31, 2024, the company had cash of $135 and a working capital deficit of $5,696,776.
• The company's ability to continue as a going concern is dependent on obtaining additional working capital funding.

Sentiment

Score: 2

Explanation: The document paints a very negative picture due to the increased net loss, critically low cash position, and the explicit statement about the company's dependence on additional funding to continue as a going concern.

Positives

• Operating expenses decreased, indicating some cost control.
• Revenue remained consistent with the previous year.

Negatives

• The net loss significantly increased due to derivative losses.
• The company has a substantial working capital deficit.
• The company's cash position is extremely low.
• There is substantial doubt about the company's ability to continue as a going concern without additional funding.

Risks

• The company's dependence on additional funding raises concerns about its long-term viability.
• The significant derivative losses indicate potential financial instability.
• The company's ability to execute its development plans is contingent on securing additional capital.
• The company's disclosure controls and procedures were deemed ineffective.

Future Outlook

The company's future is highly uncertain and dependent on securing additional funding to continue operations and execute its development plans. There is substantial doubt about the company's ability to continue as a going concern without additional funding.

Industry Context

Given the company's focus on regenerative medicine and oncology, it operates in a competitive and highly regulated industry. The company's financial struggles and dependence on external funding are not uncommon for early-stage biotech companies, but the extremely low cash position is a significant concern.

Comparison to Industry Standards

• It is difficult to compare Regen Biopharma's results to industry standards due to its early stage and unique circumstances.
• Comparable companies in the biotech sector often have significant R&D expenses, but they typically have more robust funding sources.
• The company's reliance on related-party transactions and convertible debt is higher than industry norms for established biotech firms.
• The extremely low cash balance of $135 is significantly below the average for publicly traded biotech companies, raising serious concerns about short-term solvency.

Related Party Transactions

• The company has a license agreement with Zander Therapeutics, Inc., a related party.
• The company subleases office space from BST Partners, which is controlled by the company's sole officer and director.
• The company has notes payable to related parties, including David Koos, BST Partners, and Zander Therapeutics, Inc.

Stakeholder Impact

• Shareholders face significant risk due to the company's financial instability and dependence on additional funding.
• Employees' jobs are at risk if the company cannot secure additional funding.
• The company's ability to develop and commercialize its products is uncertain, impacting potential customers.
• Creditors face increased risk of non-payment due to the company's low cash position.

Next Steps

• The company needs to secure additional funding to continue operations.
• The company needs to improve its internal controls over financial reporting.
• The company needs to manage its operating expenses effectively.

Key Dates

Keywords

financial results, Regen Biopharma, net loss, operating expenses, derivative liability, working capital, going concern, funding, biopharma